Enzo Biochem Executive Says Oral Immune Regulation Platform Shows "Therapeutic Promise"

Speaking at Bio-Europe 2009 Conference in Austria, Research and Clinical Studies for Treatment of Crohn's Disease and Uveitis Cited

VIENNA--(BUSINESS WIRE)-- Enzo Biochem, Inc. (NYSE:ENZ) today reported on the Company's therapeutic platforms utilizing oral immune regulation for immune mediated diseases at the Bio-Europe 2009 15^th Annual International Conference here calling it a "bright area of therapeutic promise."

"Our therapeutics subsidiary has long viewed oral immune regulation as an exciting and promising platform and one that we continue to pursue through studies involving treatment candidates for unmet medical needs," the meeting was told by David Goldberg, Enzo's Vice President, Corporate Development. "Additionally, as we grow our Life sciences and Clinical Labs divisions, we are utilizing the experience and knowledge gained in our drug discovery programs to better position Enzo in the rapidly growing companion diagnostics space."

He cited as examples of ongoing clinical studies:

    --  Alequel(TM), an individualized therapy for treatment of Crohn's disease.
        A multi-arm Phase 2 clinical trial, with no treatment-related
        side-effects, having met its endpoints and offering the potential to
        induce long-term remission. Current treatments have limited utility with
        potential serious side effects, and, if successful, Alequel(TM) could
        reduce the need for steroids and immunosuppressive therapy.
    --  Optiquel(TM), an oral, novel peptide for autoimmune uveitis. The
        treatment is designed to inhibit progression of autoimmune uveitis by
        inducing tolerance to intraocular antigens, resulting in reduced
        inflammation and inhibition of disease progression. A proof of concept
        trial - that could simultaneously evaluate enhancements that may have
        utility for other indications, including Alequel(TM) -- is being
        undertaken in conjunction with the National Eye Institute.

Mr. Goldberg also noted that Enzo's platform involves the use of "chronic treatments for chronic disease states", and additionally, that the Company has also made progress in the development of its drug screening platform that has yielded orally delivered small molecules having potentially significant effects for bone disorders and diabetes.

About Enzo

Enzo Biochem is engaged in the research, development, manufacture and licensing of innovative health care products and technologies based on molecular biology and genetic engineering techniques, and in providing diagnostic services to the medical community. Enzo's Life Sciences division develops, produces and markets proprietary labeling and detection products for gene sequencing, genetic analysis and immunological research among others. Its catalog of over 40,000 products serves the molecular biology, drug discovery and pathology research markets. The Company's therapeutic division is in various stages of clinical evaluation of its proprietary immune regulation medicines for uveitis and Crohn's disease and conducts pre-clinical research on several candidate compounds aimed at producing new mineral and organic bone, including technology that could provide therapy for osteoporosis and fractures, among other applications. Enzo's Clinical Labs division provides routine and esoteric reference laboratory services for physicians in the New York Metropolitan and New Jersey areas. Underpinning the Company's technology and operations is an extensive intellectual property estate in which Enzo owns or licenses over 230 patents worldwide, and has pending applications for over 200 more. For more information visit the Company's website www.enzo.com.

Except for historical information, the matters discussed in this news release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this press release.

    Source: Enzo Biochem, Inc.

Released November 4, 2009